Background

Improving the success of adjuvant treatment of breast cancer and understanding the underlying causes of interpersonal variation in the response to treatment is of utmost importance for breast cancer patients’ prognosis and survival.

Multiple factors may contribute to this inter-personal variation, including baseline gut microbiome composition, diet, immune system repertoire, and interactions among all of these factors.

It has previously been established that:

  1. Diet can shape the microbiome both in terms of composition and function.
  2. The microbiome contributes to shaping the immune system. It is thus conceivable that optimizing this axis by applying a personalised nutritional regimen based on gut microbiome profiles will boost anti-tumour immune responses and improve the efficacy of therapy in breast cancer patients.

For more information on the study, visit NCT04079270 at clinicaltrials.gov

Weizmann Patient Recruitment Video

Goals

Goals

Seerave Foundation is supporting a randomized clinical trial that assesses the effects of a personalised nutritional intervention in combination to conventional therapy in breast cancer patients.

The trial will be performed as a collaborative effort between the lab of Prof. Eran Segal at Weizmann Institute and Sheba Medical Center.

The aims of the trial are:

  1. To develop predictive algorithms from associations between nutrition, glycemic response, gut microbiota, antibody and T cell responses.
  2. With the aid of these algorithms, to validate and/or further develop personalized dietary intervention (and possibly other lifestyle) protocols which will improve clinical outcomes and minimize the use of invasive medicine.
  3. Extend these algorithms and other protocols to other cancer types.

Please find a link to the smart phone application here: https://play.google.com/store/apps/details?id=com.weizmann

The progress

Achieved Milestones

September

2021

Interim Analysis

February

2020

First participant finishing dietary intervention

July

2019

First participant recruited

March

2019

Ethical Approval

July

2018

Project Launch

Study Launch
Enrollment
Data Analysis
Wrap Up
Current status

Team

Segal Lab

Eran Segal

Principal Investigator

Michal Rein

Fellow

Thomas Vogl

Fellow